MedKoo Cat#: 562788 | Name: HIV-1 Inhibitor 18A

Description:

WARNING: This product is for research use only, not for human or veterinary use.

HIV-1 Inhibitor 18A is a specific inhibitor of the entry of a wide range of HIV-1 isolates.

Chemical Structure

HIV-1 Inhibitor 18A
HIV-1 Inhibitor 18A
CAS#331261-50-8

Theoretical Analysis

MedKoo Cat#: 562788

Name: HIV-1 Inhibitor 18A

CAS#: 331261-50-8

Chemical Formula: C14H11N5O2S

Exact Mass: 313.0633

Molecular Weight: 313.33

Elemental Analysis: C, 53.67; H, 3.54; N, 22.35; O, 10.21; S, 10.23

Price and Availability

Size Price Availability Quantity
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
HIV-1 Inhibitor 18A; HIV-1 Inhibitor-18A;
IUPAC/Chemical Name
1-(2,1,3-Benzothiadiazol-4-yl)-3-[(E)-(4-hydroxyphenyl)methyleneamino]urea
InChi Key
QRTYYEYYXURINZ-OVCLIPMQSA-N
InChi Code
InChI=1S/C14H11N5O2S/c20-10-6-4-9(5-7-10)8-15-17-14(21)16-11-2-1-3-12-13(11)19-22-18-12/h1-8,20H,(H2,16,17,21)/b15-8+
SMILES Code
O=C(N/N=C/C1=CC=C(O)C=C1)NC2=CC=CC3=NSN=C32
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 313.33 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Berinyuy E, Soliman MES. Identification of Novel Potential gp120 of HIV-1 Antagonist Using Per-Residue Energy Contribution-Based Pharmacophore modelling. Interdiscip Sci. 2017 Sep;9(3):406-418. doi: 10.1007/s12539-016-0174-7. Epub 2016 May 10. PubMed PMID: 27165479. 2: Berinyuy E, Soliman ME. A broad spectrum anti-HIV inhibitor significantly disturbs V1/V2 domain rearrangements of HIV-1 gp120 and inhibits virus entry. J Recept Signal Transduct Res. 2016;36(2):119-29. doi: 10.3109/10799893.2015.1056307. Epub 2015 Oct 8. PubMed PMID: 26446906. 3: Herschhorn A, Gu C, Espy N, Richard J, Finzi A, Sodroski JG. A broad HIV-1 inhibitor blocks envelope glycoprotein transitions critical for entry. Nat Chem Biol. 2014 Oct;10(10):845-52. doi: 10.1038/nchembio.1623. Epub 2014 Aug 31. PubMed PMID: 25174000; PubMed Central PMCID: PMC4231716. 4: Martin SF, Dorsey GO, Gane T, Hillier MC, Kessler H, Baur M, Mathä B, Erickson JW, Bhat TN, Munshi S, Gulnik SV, Topol IA. Cyclopropane-derived peptidomimetics. Design, synthesis, evaluation, and structure of novel HIV-1 protease inhibitors. J Med Chem. 1998 May 7;41(10):1581-97. PubMed PMID: 9572884.